Publications by authors named "Arthur Staddon"

35Publications

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.

Cancer 2020 01 11;126(1):105-111. Epub 2019 Sep 11.

Pennsylvania Oncology Hematology Associates, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32515
Publisher Site
http://dx.doi.org/10.1002/cncr.32515DOI Listing
January 2020

Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development.

Cancer Med 2019 02 10;8(2):585-592. Epub 2019 Jan 10.

Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cam4.1958
Publisher Site
http://dx.doi.org/10.1002/cam4.1958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382713PMC
February 2019

Combined Sclerosing and Spindle Cell Rhabdomyosarcoma in Previous Craniotomy Site: A Case Report and a Review of the Literature.

Int J Surg Pathol 2019 May 1;27(3):328-335. Epub 2018 Oct 1.

1 Department of Pathology and Laboratory Medicine, Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1066896918802030
Publisher Site
http://dx.doi.org/10.1177/1066896918802030DOI Listing
May 2019

Sertoli-Leydig Cell Tumor with Concurrent Rhabdomyosarcoma: Three Case Reports and a Review of the Literature.

Case Rep Med 2017 2;2017:4587296. Epub 2017 Jul 2.

Pennsylvania Hospital, Penn Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/4587296DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511678PMC
July 2017

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

J Clin Oncol 2016 Mar 14;34(8):786-93. Epub 2015 Sep 14.

George D. Demetri, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA; Margaret von Mehren, Fox Chase Cancer Center; Arthur Staddon, University of Pennsylvania, Philadelphia; Hussein Tawbi, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Robin L. Jones, Seattle Cancer Care Alliance, Seattle, WA; Martee L. Hensley, Memorial Sloan Kettering Cancer Center; Robert G. Maki, Mount Sinai Medical Center, New York, NY; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Anthony Elias, University of Colorado Cancer Center, Aurora, CO; Kristen Ganjoo, Stanford Hospital and Clinics, Stanford, CA; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Andrew Dean, St John of God Hospital-Bendat Cancer Centre, Subiaco, Western Australia, Australia; Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, and Trilok V. Parekh, Janssen Research & Development, Raritan, NJ; and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.4734
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559PMC
March 2016

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411366DOI Listing
July 2015

"Residual Osteocytic Lesion": Effect of Denosumab (AMG 162) Treatment on the Morphology and Immunophenotype of Giant-Cell Tumor: A Report of Two Cases.

JBJS Case Connect 2013 Jan-Mar;3(1):e10

Department of Pathology (N.D.R., K.J., and J.S.B) and Department of Medical Oncology (A.P.S.), 800 Spruce Street, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, PA 19107. E-mail address for N.D. Riddle:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2106/JBJS.CC.L.00161DOI Listing
December 2017

Improved survival after pulmonary metastasectomy for soft tissue sarcoma.

J Thorac Oncol 2011 May;6(5):913-9

Division of Thoracic Surgery, Joan Karnell Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182106f5cDOI Listing
May 2011

Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy.

Am J Clin Oncol 2011 Aug;34(4):417-21

Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, 19106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181e9c08aDOI Listing
August 2011

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

Lancet Oncol 2010 Mar 10;11(3):275-80. Epub 2010 Feb 10.

Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(10)70010-3DOI Listing
March 2010

Treatment of adult rhabdomyosarcoma.

Am J Clin Oncol 2010 Apr;33(2):128-31

Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181979222DOI Listing
April 2010

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.

Mod Pathol 2008 Mar 21;21(3):231-7. Epub 2007 Dec 21.

Department of Pathology, Pennsylvania Hospital of the University of Pennsylvania Health System, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.3800995DOI Listing
March 2008

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.

Oncologist 2005 Mar;10(3):183-90

III, The Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.10-3-183DOI Listing
March 2005

Osteogenic sarcoma presenting with lung metastasis.

Oncologist 2002 ;7(2):144-53

The Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.7-2-144DOI Listing
June 2002